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Introduction
Transthyretin (TTR) related Familial Amyloid Polyneuro-
pathy presents as a severe sensory, motor and autonomic
neuropathy. Tafamidis, an oral drug that stabilizes TTR
preventing amyloid deposition, was recently introduced in
Europe to delay neuropathy progression in ambulatory
patients.
Objectives
To present Tafamidis efficacy and safety data after 12 and
24M treatment in patients from Porto, Portugal.
Methods
Patients were evaluated at baseline, 6, 12 and 24M.
Adverse events and body mass index were registered.
Renal, thyroid, and liver functions were screened. Neuro-
pathy impairment score (NIS), the Norfolk Quality of life
(QoL) – diabetic neuropathy total score (Norfolk), this last
only at baseline, 12 and 24M. Patients were classified as
responders (NIS change across 12 and 24M<2) or non-
responders (if greater).
Paired samples t test and ANOVA with repeated mea-
sures were used.
Results
163 patients (92 males), with a mean age of 41.04 ± 11.68
years [26-80] and a mean duration of disease of 29.66 ±
17.48 months [4-90], completed a 12M evaluation. Body
mass index remained stable throughout these 12M (3.13
vs. 3.14, p<0.008).
Mean NIS score decreased from baseline to 12M (2.35
vs. 2.34, p<0.694, ns) and Norfolk score improved
between baseline and 12M (3.03 vs. 2.74, p<0.000).
Responders (n=112, 68,7%) showed a significant NIS-
score decrease between baseline and 12M (2.24 vs. 2.05,
p<0.000). Non-responders showed a significant increase
across one year (2.56 vs. 2.88, p<0.000). Nonetheless, even
in this group there was a Norfolk decreased in the same
period (3.27 vs. 3.06, p<0.020).
The group that completed a 24M evaluation consisted
of 104 patients (56 males), with a mean age of 40.04 ±
10.14 years [26-76] and a mean duration of disease of
32.03 ± 17.97 months [4-77]. Once again, body mass
index remained stable throughout 24M (3.12 vs. 3.13,
p<0.414, ns).
Mean NIS score increased from baseline to 24M (2.35
vs. 2.45, p<0.079, ns) and Norfolk score changed between
baseline and 24M (3.10 vs. 2.85, p<0.001).
Responders (n=60, 57.7%) presented a significant NIS
score decrease between baseline and 24M (2.13 vs. 1.97,
p<0.002), while non-responders showed a significant
increase across two years (2.63 vs. 3.04, p<0.000). On the
other hand, non-responders’ Norfolk decreased in the
same timespan (3.22 vs. 3.06, p<0.029).
No safety problems were detected including, renal,
thyroid and liver functions.
Conclusion
Tafamidis stabilized 69% of patients treated for one year
and 57% of patients treated for two years. Even patients
classified as non-responders according to NIS score
showed a good response both on QoL and BMI. No major
safety issues were detected.
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